Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study - Clinical Genitourinary Cancer
Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer | SpringerLink
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation | BMC Cancer
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
Votrient - NPS MedicineWise
Clinical Trials | VOTRIENT® (pazopanib) tablets
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma | PNAS
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Survival distributions for progression-free (PFS) and overall survival... | Download Scientific Diagram
820-Renal cell metastatic pAZOPanib | eviQ
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Votrient, pazopanib
The Impact of Pazopanib on the Cardiovascular System - Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith, 2018
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation | BMC Cancer
Progression free survival for patient with metastatic bone sarcoma... | Download Scientific Diagram
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial - Annals of Oncology
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer | Future Oncology
